Abstract
Cancer is one of the leading causes of death worldwide, and current research has focused on the discovery of novel approaches to effectively treat this disease. Recently, a considerable number of clinical trials have demonstrated the success of immunomodulatory therapies for the treatment of cancer. Monoclonal antibodies can target components of the immune system to either i) agonise co-stimulatory molecules, such as CD137, OX40 and CD40; or ii) inhibit immune checkpoints, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1) and its corresponding ligand PD-L1. Although tumour regression is the outcome for some patients following immunotherapy, many patients still do not respond. Furthermore, chemotherapy has been the standard of care for most cancers, but the immunomodulatory capacity of these drugs has only recently been uncovered. The ability of chemotherapy to modulate the immune system through a variety of mechanisms, including immunogenic cell death (ICD), increased antigen presentation and depletion of regulatory immune cells, highlights the potential for synergism between conventional chemotherapy and novel immunotherapy. In addition, recent pre-clinical trials indicate dipeptidyl peptidase (DPP) enzyme inhibition, an enzyme that can regulate immune cell trafficking to the tumour microenvironment, as a novel cancer therapy. The present review focuses on the current immunological approaches for the treatment of cancer, and summarizes clinical trials in the field of immunotherapy as a single treatment and in combination with chemotherapy.
Keywords: Immunotherapy, immunomodulation, chemotherapy, CTLA-4, PD-1, PD-L1, CD137.
Current Medicinal Chemistry
Title:New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators
Volume: 25 Issue: 36
Author(s): Amy L. Wilson, Magdalena Plebanski*Andrew N. Stephens*
Affiliation:
- Department of Immunology and Pathology, Monash University, Melbourne,Australia
- Centre for Cancer Research, Hudson Institute of Medical Research, Clayton,Australia
Keywords: Immunotherapy, immunomodulation, chemotherapy, CTLA-4, PD-1, PD-L1, CD137.
Abstract: Cancer is one of the leading causes of death worldwide, and current research has focused on the discovery of novel approaches to effectively treat this disease. Recently, a considerable number of clinical trials have demonstrated the success of immunomodulatory therapies for the treatment of cancer. Monoclonal antibodies can target components of the immune system to either i) agonise co-stimulatory molecules, such as CD137, OX40 and CD40; or ii) inhibit immune checkpoints, such as cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4), programmed cell death-1 (PD-1) and its corresponding ligand PD-L1. Although tumour regression is the outcome for some patients following immunotherapy, many patients still do not respond. Furthermore, chemotherapy has been the standard of care for most cancers, but the immunomodulatory capacity of these drugs has only recently been uncovered. The ability of chemotherapy to modulate the immune system through a variety of mechanisms, including immunogenic cell death (ICD), increased antigen presentation and depletion of regulatory immune cells, highlights the potential for synergism between conventional chemotherapy and novel immunotherapy. In addition, recent pre-clinical trials indicate dipeptidyl peptidase (DPP) enzyme inhibition, an enzyme that can regulate immune cell trafficking to the tumour microenvironment, as a novel cancer therapy. The present review focuses on the current immunological approaches for the treatment of cancer, and summarizes clinical trials in the field of immunotherapy as a single treatment and in combination with chemotherapy.
Export Options
About this article
Cite this article as:
Wilson L. Amy, Plebanski Magdalena *, Stephens N. Andrew *, New Trends in Anti-Cancer Therapy: Combining Conventional Chemotherapeutics with Novel Immunomodulators, Current Medicinal Chemistry 2018; 25 (36) . https://dx.doi.org/10.2174/0929867324666170830094922
DOI https://dx.doi.org/10.2174/0929867324666170830094922 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
Call for Papers in Thematic Issues
Advances in Medicinal Chemistry: From Cancer to Chronic Diseases.
The broad spectrum of the issue will provide a comprehensive overview of emerging trends, novel therapeutic interventions, and translational insights that impact modern medicine. The primary focus will be diseases of global concern, including cancer, chronic pain, metabolic disorders, and autoimmune conditions, providing a broad overview of the advancements in ...read more
Cellular and Molecular Mechanisms of Non-Infectious Inflammatory Diseases: Focus on Clinical Implications
The Special Issue covers the results of the studies on cellular and molecular mechanisms of non-infectious inflammatory diseases, in particular, autoimmune rheumatic diseases, atherosclerotic cardiovascular disease and other age-related disorders such as type II diabetes, cancer, neurodegenerative disorders, etc. Review and research articles as well as methodology papers that summarize ...read more
Chalcogen-modified nucleic acid analogues
Chalcogen-modified nucleosides, nucleotides and oligonucleotides have been of great interest to scientific research for many years. The replacement of oxygen in the nucleobase, sugar or phosphate backbone by chalcogen atoms (sulfur, selenium, tellurium) gives these biomolecules unique properties resulting from their altered physical and chemical properties. The continuing interest in ...read more
Current advances in inherited cardiomyopathy
Describe in detail all novel advances in multimodality imaging related to inherited cardiomyopathy diagnosis and prognosis. Shed light to deeper phenotypic characterization. Acknowledge recent advances in genetics, genomics and precision medicineread more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Preface
Current Pharmaceutical Design Understanding Heterogeneity in Supplementation Effects of Selenium in Men: A Study of Stratification Variables and Human Genetics in a Prospective Sample from New Zealand
Current Pharmacogenomics and Personalized Medicine Nanomedicine Advances in Topical Infective and Non-Infective Skin Diseases Therapy
Recent Patents on Anti-Infective Drug Discovery Recent Progress in the Development of Quinoline Derivatives for the Exploitation of Anti-Cancer Agents
Anti-Cancer Agents in Medicinal Chemistry Five Common Functional Polymorphisms in microRNAs (rs2910164, rs2292832, rs11614913, rs3746444, rs895819) and the Susceptibility to Breast Cancer: Evidence from 8361 Cancer Cases and 8504 Controls
Current Pharmaceutical Design Red and NIR Light-Responsive Polymeric Nanocarriers for On-Demand Drug Delivery
Current Medicinal Chemistry MicroRNAs as Therapeutic Agents: The Future of the Battle Against Cancer
Current Topics in Medicinal Chemistry Trebananib (AMG 386): A Non-VEGF Antiangiogenesis Option in Women with Ovarian Cancer
Current Angiogenesis (Discontinued) Corrosion Protection Performance via Nano-Coatings Technologies
Recent Patents on Materials Science Modelling DNA Repair Pathways: Recent Advances and Future Directions
Current Pharmaceutical Design Lipids as a Target for Drugs Modulating Multidrug Resistance of Cancer Cells
Current Drug Targets LDH Nanocontainers as Bio-Reservoirs and Drug Delivery Carriers
Recent Patents on Nanotechnology Liposomal Muramyl Tripeptide Phosphatidylethanolamine: Targeting and Activating Macrophages for Adjuvant Treatment of Osteosarcoma
Current Cancer Drug Targets Interactions between Transporters and Herbal Medicines/Drugs: A Focus on Hepatoprotective Compounds
Current Drug Metabolism Natural and Synthetic Naphthoquinones Active Against Trypanosoma Cruzi: An Initial Step Towards New Drugs for Chagas Disease
Current Medicinal Chemistry Biomarkers in Molecularly Targeted Therapy for Cancer
Recent Patents on Biomarkers Preface
Current Cancer Drug Targets Functional Genomic Approaches Targeting the Wnt Signaling Network
Current Drug Targets A Computational Approach to Identify Novel Potential Precursor miRNAs and their Targets from Hepatocellular Carcinoma Cells
Current Bioinformatics Subject index to volume 1
Current HIV Research